AU2001249380A1 - Compositions and methods for generating an immune response utilizing alphavirus-based vector systems - Google Patents

Compositions and methods for generating an immune response utilizing alphavirus-based vector systems

Info

Publication number
AU2001249380A1
AU2001249380A1 AU2001249380A AU4938001A AU2001249380A1 AU 2001249380 A1 AU2001249380 A1 AU 2001249380A1 AU 2001249380 A AU2001249380 A AU 2001249380A AU 4938001 A AU4938001 A AU 4938001A AU 2001249380 A1 AU2001249380 A1 AU 2001249380A1
Authority
AU
Australia
Prior art keywords
compositions
generating
methods
immune response
vector systems
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001249380A
Inventor
Susan Barnett
David A Driver
Thomas W. Dubensky Jr.
Ilya Frolov
Jason P. Gardner
Gillis Otten
John M Polo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU2001249380A1 publication Critical patent/AU2001249380A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001249380A 2000-03-22 2001-03-22 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems Abandoned AU2001249380A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19136300P 2000-03-22 2000-03-22
US60191363 2000-04-22
PCT/US2001/009326 WO2001081609A2 (en) 2000-03-22 2001-03-22 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems

Publications (1)

Publication Number Publication Date
AU2001249380A1 true AU2001249380A1 (en) 2001-11-07

Family

ID=22705178

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001249380A Abandoned AU2001249380A1 (en) 2000-03-22 2001-03-22 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems

Country Status (2)

Country Link
AU (1) AU2001249380A1 (en)
WO (1) WO2001081609A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2266656A1 (en) 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
ATE350015T1 (en) 2000-09-28 2007-01-15 Novartis Vaccines & Diagnostic MICROPARTICLE COMPOSITIONS AND METHODS FOR THEIR PRODUCTION
CN1468089B (en) * 2000-09-28 2011-09-21 诺华疫苗和诊断公司 Microparticles for delivery of the heterologous nucleic acids
ES2345876T3 (en) 2001-05-31 2010-10-05 Novartis Vaccines And Diagnostics, Inc. PARTICLES OF CHEMICAL ALFAVIRUS REPLICATIONS.
CA2476626A1 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
EP2263687B1 (en) 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
ES2596553T3 (en) 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Immunogenic compositions based on microparticles comprising adsorbed toxoid and an antigen containing a polysaccharide
WO2006078294A2 (en) * 2004-05-21 2006-07-27 Novartis Vaccines And Diagnostics Inc. Alphavirus vectors for respiratory pathogen vaccines
EP1814583A2 (en) * 2004-11-01 2007-08-08 Novartis Vaccines and Diagnostics, Inc. Combination approaches for generating immune responses
CN107033243B (en) 2005-03-23 2020-12-15 根马布股份公司 CD38 antibodies for the treatment of multiple myeloma
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
JP2011500036A (en) 2007-10-15 2011-01-06 ザ ユニバーシティー オブ クイーンズランド Construct systems and their use
KR101383476B1 (en) 2007-11-01 2014-04-11 아스테라스 세이야쿠 가부시키가이샤 Immunosuppressive polypeptides and nucleic acids
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
WO2015073707A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2
WO2017004022A2 (en) 2015-06-29 2017-01-05 The Board Of Trustees Of The Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production
CN108601951B (en) 2015-12-09 2022-11-22 金港医疗(澳大利亚)私人有限公司 Immunomodulatory compositions for treatment
EP4419684A1 (en) 2021-10-21 2024-08-28 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Retroelement-generated transcription factor decoys
CA3237482A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023183588A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Methods of assessing engineered retron activity, and uses thereof
WO2023183589A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Rt-dna fidelity and retron genome editing
WO2023183627A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna
WO2024020346A2 (en) 2022-07-18 2024-01-25 Renagade Therapeutics Management Inc. Gene editing components, systems, and methods of use
WO2024044673A1 (en) 2022-08-24 2024-02-29 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Dual cut retron editors for genomic insertions and deletions
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
CN118086395B (en) * 2024-04-25 2024-06-21 南京农业大学三亚研究院 Gaita virus plasmid vector, attenuated strain, preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator

Also Published As

Publication number Publication date
WO2001081609A2 (en) 2001-11-01
WO2001081609A3 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
AU2001249380A1 (en) Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
WO2000061772A3 (en) Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
AU2001268627A1 (en) Compositions and methods for generating expression vectors through site-specificrecombination
AU2008243079A1 (en) Compositions and methods for generating an immune response
AU2001255610A1 (en) System and method related to generating and tracking an email campaign
AU2001298063A1 (en) Methods and systems for generating business models
IL145314A0 (en) Advertisements in an end-user controlled playback environment
AU2001265154A1 (en) Method and composition for targeting an adenoviral vector
WO2002017157A8 (en) Marketing systems and methods
AU2001258701A1 (en) Systems and methods for presenting and/or converting messages
AU2001275762A1 (en) Simulation system
AU2002224346A1 (en) Thermoelectric generators
AU4806100A (en) P element derived vector and methods for its use
AU2001255205A1 (en) Systems and methods for generating computer-displayed presentations
AU2001247496A1 (en) Methods and systems for providing an electronic account to customer
AU2001231635A1 (en) Keep-fit device in the form of an item of clothing
MXPA03005579A (en) Branched primary alcohol compositions and derivatives thereof.
GB2368463B (en) Auto-contactor system and method for generating variable size contacts
AU2002309486A1 (en) Methods and compositions for modulating the immune system of animals
AU2001255677A1 (en) Systems and methods for generating an appliance with tie points
AU1803401A (en) Methods and systems for generating tractograms
AU2001241996A1 (en) Rule based proximity and time based tracking system
AU2001275409A1 (en) Methods and compositions for controlled polypeptide synthesis
AU2001253481A1 (en) Methods and compositions for eleciting an immune response
AU4866201A (en) Compositions and methods for use in modulating immune system function